Incyte Corp logo

Incyte Corp

$ 71.40 (0%) Dec 2
On watch
P/E:
20.53
P/B:
4.25
Market Cap:
$ 17.95B
Enterprise V:
$ 15.01B
Volume:
-
Avg Vol (2M):
-
Also Trade In:
Volume:
-
Market Cap $:
17.95B
PE Ratio:
20.53
Avg Vol (2-Month):
-
Enterprise Value $:
15.01B
PB Ratio:
4.25
GF Score:
Year:
Not Enough Data to Display
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Not Enough Data to Display
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Name Current Vs Industry Vs History
Cash-To-Debt 70.75
Equity-to-Asset 0.77
Debt-to-Equity 0.01
Debt-to-EBITDA 0.07
Interest Coverage 221.55
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 9.83
Distress
Grey
Safe
Beneish M-Score -2.15
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.8
Quick Ratio 3.75
Cash Ratio 2.96
Days Inventory 70.46
Days Sales Outstanding 65.67
Days Payable 303.54

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -1.2

Financials (Next Earnings Date:2023-02-08 Est.)

LTS:0J9P's 30-Y Financials

Guru Trades

See Details
To
Not Enough Data to Display

Insider Trades

See Details
To
Not Enough Data to Display

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
Not Enough Data to Display

Performance

Dividend
Log
To
Not Enough Data to Display

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Not Enough Data to Display

Valuation Box

Year:
Not Enough Data to Display

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 3,330.788
EPS (TTM) ($) 3.93
Beta 0.25
Volatility % 0
14-Day RSI 0
14-Day ATR ($) 0
20-Day SMA ($) 71.4
12-1 Month Momentum % 0
52-Week Range ($) 71.4 - 71.4
Shares Outstanding (Mil) 222.48

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Incyte Corp Filings

Document Form Filing Date
No Filing Data

Incyte Corp Analysis

Share your research